18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: Preclinical evaluation in an orthotopic rat model

Journal of Nuclear Medicine

Volumn 50, Issue 9, 2009, Pages 1533-1540

  Dutour, Aurélie ^a,c   Decouvelaere, Anne Valérie ^b,c   Monteil, Jacques ^d   Duclos, Marie Eve ^e   Roualdes, Olivier ^e   Rousseau, Raphaël ^c,e,f   Marec Bérard, Perrine ^c,f  

^a INSERM   (France)

^b Département d'Anatomopathologie et Cytologie   (France)

^c CENTRE LÉON BÉRARD   (France)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE LYON   (France)

^f Institut d'Hématologie Oncologie Pédiatrique   (France)

Author keywords

18F FDG PET; Histologic response; Metabolic response; Osteosarcoma; SUVmax

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG UPTAKE; HISTOPATHOLOGY; MEASUREMENT; METABOLISM; NONHUMAN; OSTEOSARCOMA; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BONE TUMOR; DISEASE MODEL; DRUG SCREENING; HUMAN; METABOLIC CLEARANCE RATE; METHODOLOGY; PATHOLOGY; SCINTISCANNING; SPRAGUE DAWLEY RAT; STATISTICS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FLUORODEOXYGLUCOSE F18; HUMANS; METABOLIC CLEARANCE RATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 69449090085     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.062356     Document Type: Article

References (28)

1. Marec-Bérard C. Ostéosarcomes de l'enfant. Oncologie. 2006;8:546-550.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790. (Pubitemid 34111386)
3. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134:281-297. (Pubitemid 351170066)
4. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18. (Pubitemid 8190735)
5. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol. 2006;16:2637-2643. (Pubitemid 44823917)
6. Uhl M, Saueressig U, Koehler G, et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol. 2006;36:1306-1311. (Pubitemid 44920869)
7. van der Woude HJ, Bloem JL, Holscher HC, et al. Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging. Skeletal Radiol. 1994;23:493-500. (Pubitemid 24316522)
8. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292. (Pubitemid 46606405)
9. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14:715-720. (Pubitemid 351231152)
10. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83-101. (Pubitemid 38240089)
11. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507. (Pubitemid 43200300)
12. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348. (Pubitemid 40129294)
13. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol. 2006;18:369-373. (Pubitemid 44297249)
14. Dutour A, Monteil J, Paraf F, et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther. 2005;11:311-319.
15. Dutour A, Leclers D, Monteil J, et al. Non-invasive imaging correlates with histological and molecular characteristics of an osteosarcoma model: application for early detection and follow-up of MDR phenotype. Anticancer Res. 2007;27:4171-4178.
16. 144cerium in rats as a model for human osteosarcomas. Int J Cancer. 1980;26:777-782.
17. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48:1761-1766.
18. Vera P, Ouvrier MJ, Hapdey S, et al. Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging. 2007;34:1943-1952.
19. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
20. Coffin CM, Lowichik A, Zhou H. Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol. 2005;123:75-90. (Pubitemid 40066173)
21. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423-436. (Pubitemid 44309249)
22. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664.
23. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996;37:257-261. (Pubitemid 26150898)
24. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008;8:94-107. (Pubitemid 351161320)
25. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15:61-66. (Pubitemid 19054851)
26. 18F] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.
27. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis. 2004;32:182-190.
28. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42. (Pubitemid 44201576)